Risk Perception of SARS-CoV-2 Infection and Acceptability of a COVID-19 Vaccine in Nigeria

Résumé

Abstract Background: Vaccines are highly anticipated for the control of the ongoing COVID-19 pandemic, however their acceptance is critical for the desired benefit. This study assessed risk perception of COVID-19 and acceptability of its vaccine in Nigeria. It also assessed prediction of vaccine acceptance from risk perception. Methods: A cross-sectional web-based study was conducted among 410 participants in the six geo-political regions of Nigeria using a three-part questionnaire developed using Google forms. The questionnaire link was distributed via snowball method to consenting participants through online platforms. Descriptive and inferential statistics (Chi-square and binomial regression) using Microsoft Excel and SPSS version 24 were used to analyze data, and p-values < 0.05 were considered statistically significant.Results: A total of 410 respondents participated in the study and high risk perception of SARS-CoV-2 infection (COVID-19) was seen in 127(66.1%) of respondents. Vaccine acceptance was high in 233(56.8%) of respondents, and was significantly associated with geo-political region (P=0.028). Association between COVID-19 risk perception and vaccine acceptance showed that persons who had high risk perception of COVID-19 may not necessarily accept the vaccine (OR=0.450; 95% CI=0.297–0.683; P=0.000) and this was seen in persons with tertiary education (OR=0.458; 95% CI=0.297-0.706; P=0.000), married (OR=0.194; 955%CI =0.098-0.386; P=0.000), from South-south (OR=0.352; 95%CI=0.163–0.760; P=0.008) and North-central (OR=0.429; 95% CI= 0.189-0.972; P=0.043).Conclusions: High risk perception of COVID-19, and vaccine acceptance were relatively average. Regional and socio-demographic variations were associated with this finding, and it was also noted that high risk perception of COVID-19 may not likely result in vaccine acceptance. Strategic and targeted messaging on vaccine acceptance should be prioritised by stakeholders, to ensure successful vaccine implementation.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0